A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers ; volume:8 ; number:1 ; day:23 ; month:4 ; year:2024 ; pages:1-16 ; date:12.2024
npj precision oncology ; 8, Heft 1 (23.4.2024), 1-16, 12.2024
- Creator
-
Zhou, Dan-dan
Zhai, Xiao-tian
Zhang, Lan-wen
Xie, Zi-hui
Wang, Ying
Zhen, Yong-su
Gao, Rui-juan
Miao, Qing-fang
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41698-024-00584-z
- URN
-
urn:nbn:de:101:1-2407090928524.401019995109
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zhou, Dan-dan
- Zhai, Xiao-tian
- Zhang, Lan-wen
- Xie, Zi-hui
- Wang, Ying
- Zhen, Yong-su
- Gao, Rui-juan
- Miao, Qing-fang
- SpringerLink (Online service)
Other Objects (12)
The First FDA-Approved Antibody-Drug Conjugate
Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer
Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Author Correction: Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors
A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
The First FDA-Approved Antibody-Drug Conjugate
Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer
Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Author Correction: Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors
A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
The First FDA-Approved Antibody-Drug Conjugate
Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer
Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Author Correction: Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors
A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers